Related Experiment Video
Updated: Jun 15, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
[Treatment options in non-Hodgkin lymphomas]
1Service hématologie, Centre Henri-Becquerel, 76038 Rouen. herve.tilly@rouen.fnclcc.fr
Abstract:
Histological diagnosis according to WHO classification and determination of usual prognostic factors are necessary to choose between treatment options in non-Hodgkin lymphomas. If an observation period could be frequently proposed to patients with indolent lymphoma, first line treatment usually includes the anti-CD20 monoclonal antibody rituximab (in type B lymphoma or CD20-expressing). A complete remission must be obtained in patients with aggressive lymphoma and the association of chemotherapy and rituximab, in B-cell subtype, is the standard therapeutic approach.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers
Treatment Resistant Cancers
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

